NovaBone Announces Irrigation Resistant Products with Carriers that have Synergistic Effect in Bone Formation

This Week’s News in Review

This Week's News in Review! Medical Device News Magazine keeps our readers up-to-date on breaking industry news! Learn how Medical Device News Magazine can help...

New Research Shows Nearly Half of Elderly Suffer Decreased Mobility During Lockdown

In a survey of UK adults with parents over the age of 75, while over half (52%) of respondents remain worried about their parents catching Covid, 48 percent are concerned about parental loneliness, and 46 percent about their parents falling alone and not being able to get up or get help. This figure remained high even among those whose parents are in care homes, with 37% of respondents still most concerned about parents falling over.

American College of Cardiology Names Ravee Kurian COO/CFO

Kurian comes to ACC following a 20-year stint at Publicis Sapient, a leading technology and communications consultancy, where he led critical and sensitive digital transformation initiatives for Fortune 500 and U.S. federal clients.

IRM delivery systems

NovaBone Products, a leading biologics medical device company, announces the addition of NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically active bone graft substitutes.

NovaBone IRM, and NovaBone IRM MacroPOR are the most advanced bioactive synthetic bone graft substitutes available to the orthopedic community today. Both formulations optimize osteogenesis, uniquely signal and stimulate osteoblastic activity, and offer angiogenic potential. By design, both formulations are highly irrigation resistant with excellent cohesion and handling properties.

“NovaBone Products’ base Bioactive Glass technology has proven to out-perform traditional calcium sulfate based synthetic products and demineralized bone matrix products,” said Dennis McBride, Vice President of Sales and Marketing. “We are now advancing our science further by providing formulations with carriers that have a synergistic effect in bone formation and retain molded shapes following implantation and irrigation.”

Novabone offers the broadest portfolio of bioactive synthetic bone graft substitutes in the world, with a robust pipeline of products in development designed to expand the regenerative biologics products the company offers. Presently, products offered include minimally invasive (MIS) delivery devices, strip formulations, putty materials that are hydrated using bone marrow aspirate, and putty formulations that are ready-to-use out of the package.

“We are proud to offer products that allow a surgeon to look to one company when addressing bone grafting needs,” concluded McBride.

NovaBone Products, a privately held company based in Florida, USA since 2002 and a recognized industry leader in bioactive glass design and manufacturing, developed the first bioactive synthetic bone graft offered to the orthopaedic community.

spot_img

DON'T MISS

Dr Jonathan Slotkin Appointed to Peer Well Board of Directors

Alongside the appointment, PeerWell is launching its new clinical practice, PeerWell Health.

Zimmer Biomet Announces New Appointments to Executive Leadership Team

Wilfred van Zuilen Appointed as President of Europe, Middle East and Africa. Nitin Goyal, M.D. Appointed to Newly Created Role of Chief Science, Technology and Innovation Officer.

Subscribe to Medical Device News Magazine here.

Related Articles